The immunological functions of muramyl dipeptide compound adjuvant on humoral, cellular-mediated and mucosal immune responses to PEDV inactivated vaccine in mice

Chuan J. Zhou, Jin Chen, Ji B. Hou, Yang Zheng, Yuan N. Yu, Hui He, Yuan P. Zhang, Xiuli Feng, Qi S. Zheng

Research output: Contribution to journalArticle

Abstract

Background: The muramyl dipeptide compound adjuvant, CVC1303, was one new resigned adjuvant to PEDV inactivated vaccine. Exploring the effects of CVC1303 on the immune induction to PEDV vaccine was of vital importance to the clinical application. Objectives: Here we explored the functions of CVC1303 on the humoral, cellular and mucosal immune response to PEDV vaccine in mice immunization. Methods: Mice were twice subcutaneously injected with PEDV vaccine including high, medium and low dosages CVC1303, respectively. On 30 th day after the second immunization, sera samples were collected from the immunized mice to measure PEDV-specific IgG and IgG subclasses levels, and lymphocytes were isolated to detect T cell subtype and intracellular IL-4 and IL-6 cytokine productions, and the expressions of co-stimulatory molecule on dendritic cells in the immunized mice. Small intestinal and lung washings were collected on 30 th and 47 th day after the second immunization to measure PEDV-specific IgA levels, and SP immunohistochemical method staining was employed to analyze the deviations of IgA+ positive cells in the small intestinal of the immunized mice. Results: Our investigation proved the strong regulatory roles of CVC1303 on PEDV-specific IgG and IgG1 antibody and cytokines productions, and the significant increased CD3+CD4+T cells subpopulation and expressions of co-stimulatory molecules on dendritic cells in the immunized mice. Moreover, our findings verified the significantly enhanced PEDV-specific IgA antibody titers in small intestinal and lung in the mice immunized with PEDV vaccine and CVC1303. Conclusion: Compound adjuvant CVC1303 could effectively improve the PEDV-specific immune responses and mucosal immune, which provided an experimental basis for the further clinical application of new adjuvant CVC1303 and the development of improvement on the mucosal immune response.

Original languageEnglish (US)
Pages (from-to)908-913
Number of pages6
JournalProtein and Peptide Letters
Volume25
Issue number10
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Acetylmuramyl-Alanyl-Isoglutamine
Mucosal Immunity
Inactivated Vaccines
Immunization
Cellular Immunity
Vaccines
Immunoglobulin G
Immunoglobulin A
T-cells
Cytokines
Molecules
Lymphocytes
Antibodies
Dendritic Cells
Washing
Interleukin-4
Interleukin-6
T-Lymphocytes
Cells
Lung

Keywords

  • Antibody response
  • Cellular-mediated response
  • Compound adjuvant CVC1303
  • DC cell costimulatory factor
  • IgA
  • Porcine epidemic diarrhea virus inactivated vaccine

ASJC Scopus subject areas

  • Structural Biology
  • Biochemistry

Cite this

The immunological functions of muramyl dipeptide compound adjuvant on humoral, cellular-mediated and mucosal immune responses to PEDV inactivated vaccine in mice. / Zhou, Chuan J.; Chen, Jin; Hou, Ji B.; Zheng, Yang; Yu, Yuan N.; He, Hui; Zhang, Yuan P.; Feng, Xiuli; Zheng, Qi S.

In: Protein and Peptide Letters, Vol. 25, No. 10, 01.01.2018, p. 908-913.

Research output: Contribution to journalArticle

Zhou, Chuan J. ; Chen, Jin ; Hou, Ji B. ; Zheng, Yang ; Yu, Yuan N. ; He, Hui ; Zhang, Yuan P. ; Feng, Xiuli ; Zheng, Qi S. / The immunological functions of muramyl dipeptide compound adjuvant on humoral, cellular-mediated and mucosal immune responses to PEDV inactivated vaccine in mice. In: Protein and Peptide Letters. 2018 ; Vol. 25, No. 10. pp. 908-913.
@article{3c561f3712f0428e87db3b053166b6e6,
title = "The immunological functions of muramyl dipeptide compound adjuvant on humoral, cellular-mediated and mucosal immune responses to PEDV inactivated vaccine in mice",
abstract = "Background: The muramyl dipeptide compound adjuvant, CVC1303, was one new resigned adjuvant to PEDV inactivated vaccine. Exploring the effects of CVC1303 on the immune induction to PEDV vaccine was of vital importance to the clinical application. Objectives: Here we explored the functions of CVC1303 on the humoral, cellular and mucosal immune response to PEDV vaccine in mice immunization. Methods: Mice were twice subcutaneously injected with PEDV vaccine including high, medium and low dosages CVC1303, respectively. On 30 th day after the second immunization, sera samples were collected from the immunized mice to measure PEDV-specific IgG and IgG subclasses levels, and lymphocytes were isolated to detect T cell subtype and intracellular IL-4 and IL-6 cytokine productions, and the expressions of co-stimulatory molecule on dendritic cells in the immunized mice. Small intestinal and lung washings were collected on 30 th and 47 th day after the second immunization to measure PEDV-specific IgA levels, and SP immunohistochemical method staining was employed to analyze the deviations of IgA+ positive cells in the small intestinal of the immunized mice. Results: Our investigation proved the strong regulatory roles of CVC1303 on PEDV-specific IgG and IgG1 antibody and cytokines productions, and the significant increased CD3+CD4+T cells subpopulation and expressions of co-stimulatory molecules on dendritic cells in the immunized mice. Moreover, our findings verified the significantly enhanced PEDV-specific IgA antibody titers in small intestinal and lung in the mice immunized with PEDV vaccine and CVC1303. Conclusion: Compound adjuvant CVC1303 could effectively improve the PEDV-specific immune responses and mucosal immune, which provided an experimental basis for the further clinical application of new adjuvant CVC1303 and the development of improvement on the mucosal immune response.",
keywords = "Antibody response, Cellular-mediated response, Compound adjuvant CVC1303, DC cell costimulatory factor, IgA, Porcine epidemic diarrhea virus inactivated vaccine",
author = "Zhou, {Chuan J.} and Jin Chen and Hou, {Ji B.} and Yang Zheng and Yu, {Yuan N.} and Hui He and Zhang, {Yuan P.} and Xiuli Feng and Zheng, {Qi S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/0929866525666180917160926",
language = "English (US)",
volume = "25",
pages = "908--913",
journal = "Protein and Peptide Letters",
issn = "0929-8665",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - The immunological functions of muramyl dipeptide compound adjuvant on humoral, cellular-mediated and mucosal immune responses to PEDV inactivated vaccine in mice

AU - Zhou, Chuan J.

AU - Chen, Jin

AU - Hou, Ji B.

AU - Zheng, Yang

AU - Yu, Yuan N.

AU - He, Hui

AU - Zhang, Yuan P.

AU - Feng, Xiuli

AU - Zheng, Qi S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The muramyl dipeptide compound adjuvant, CVC1303, was one new resigned adjuvant to PEDV inactivated vaccine. Exploring the effects of CVC1303 on the immune induction to PEDV vaccine was of vital importance to the clinical application. Objectives: Here we explored the functions of CVC1303 on the humoral, cellular and mucosal immune response to PEDV vaccine in mice immunization. Methods: Mice were twice subcutaneously injected with PEDV vaccine including high, medium and low dosages CVC1303, respectively. On 30 th day after the second immunization, sera samples were collected from the immunized mice to measure PEDV-specific IgG and IgG subclasses levels, and lymphocytes were isolated to detect T cell subtype and intracellular IL-4 and IL-6 cytokine productions, and the expressions of co-stimulatory molecule on dendritic cells in the immunized mice. Small intestinal and lung washings were collected on 30 th and 47 th day after the second immunization to measure PEDV-specific IgA levels, and SP immunohistochemical method staining was employed to analyze the deviations of IgA+ positive cells in the small intestinal of the immunized mice. Results: Our investigation proved the strong regulatory roles of CVC1303 on PEDV-specific IgG and IgG1 antibody and cytokines productions, and the significant increased CD3+CD4+T cells subpopulation and expressions of co-stimulatory molecules on dendritic cells in the immunized mice. Moreover, our findings verified the significantly enhanced PEDV-specific IgA antibody titers in small intestinal and lung in the mice immunized with PEDV vaccine and CVC1303. Conclusion: Compound adjuvant CVC1303 could effectively improve the PEDV-specific immune responses and mucosal immune, which provided an experimental basis for the further clinical application of new adjuvant CVC1303 and the development of improvement on the mucosal immune response.

AB - Background: The muramyl dipeptide compound adjuvant, CVC1303, was one new resigned adjuvant to PEDV inactivated vaccine. Exploring the effects of CVC1303 on the immune induction to PEDV vaccine was of vital importance to the clinical application. Objectives: Here we explored the functions of CVC1303 on the humoral, cellular and mucosal immune response to PEDV vaccine in mice immunization. Methods: Mice were twice subcutaneously injected with PEDV vaccine including high, medium and low dosages CVC1303, respectively. On 30 th day after the second immunization, sera samples were collected from the immunized mice to measure PEDV-specific IgG and IgG subclasses levels, and lymphocytes were isolated to detect T cell subtype and intracellular IL-4 and IL-6 cytokine productions, and the expressions of co-stimulatory molecule on dendritic cells in the immunized mice. Small intestinal and lung washings were collected on 30 th and 47 th day after the second immunization to measure PEDV-specific IgA levels, and SP immunohistochemical method staining was employed to analyze the deviations of IgA+ positive cells in the small intestinal of the immunized mice. Results: Our investigation proved the strong regulatory roles of CVC1303 on PEDV-specific IgG and IgG1 antibody and cytokines productions, and the significant increased CD3+CD4+T cells subpopulation and expressions of co-stimulatory molecules on dendritic cells in the immunized mice. Moreover, our findings verified the significantly enhanced PEDV-specific IgA antibody titers in small intestinal and lung in the mice immunized with PEDV vaccine and CVC1303. Conclusion: Compound adjuvant CVC1303 could effectively improve the PEDV-specific immune responses and mucosal immune, which provided an experimental basis for the further clinical application of new adjuvant CVC1303 and the development of improvement on the mucosal immune response.

KW - Antibody response

KW - Cellular-mediated response

KW - Compound adjuvant CVC1303

KW - DC cell costimulatory factor

KW - IgA

KW - Porcine epidemic diarrhea virus inactivated vaccine

UR - http://www.scopus.com/inward/record.url?scp=85059273981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059273981&partnerID=8YFLogxK

U2 - 10.2174/0929866525666180917160926

DO - 10.2174/0929866525666180917160926

M3 - Article

VL - 25

SP - 908

EP - 913

JO - Protein and Peptide Letters

JF - Protein and Peptide Letters

SN - 0929-8665

IS - 10

ER -